Nachrichten zur BIOARCTIC AB B Aktie

Bulletin from the Annual General Meeting in BioArctic AB (publ)

Stockholm, 22 May 2025. Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm today, whereby…

BioArctic receives positive opinion for Orphan Medicinal Product Designation in the EU for exidavnemab in Multiple System Atrophy

Stockholm, May 22, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that The European Medicines Agency (EMA)…

Interim Report for the period January – March 2025

Leqembi approved in the EU and billion-dollar license agreement with Bristol Myers Squibb came into effect Events during the first quarter…

Eisai projects Leqembi® revenue to total JPY 76.5 billion for fiscal year 2025 (April 2025 – March 2026)

Stockholm, Sweden, May 15, 2025 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales…

Exidavnemab phase 2a study expanded to include MSA patients

Stockholm, May 8, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that regulatory authorities in Spain in…

Sales of Leqembi[®] totaled 14.7 billion yen in the first quarter 2025

Stockholm, Sweden, May 1, 2025 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global…

BioArctic receives European substance patent for exidavnemab

Stockholm, April 22, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office, EPO,…

BioArctic publishes the Annual Report and Sustainability Report for 2024

Stockholm, April 22, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that the Annual Report for 2024 has…

Notice of Annual General Meeting 2025 in BioArctic AB (publ)

The board of directors of BioArctic AB has resolved to convene an Annual General Meeting of shareholders to be held…

EU approves Leqembi® (lecanemab) for treatment of early Alzheimer’s disease (Extended information)

Stockholm, April 16, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has announced that the European Commission…

EU approves Leqembi® (lecanemab) for treatment of early Alzheimer’s disease

Stockholm, April 15, 2025 – The European Commission has today communicated that it has granted BioArctic AB’s (publ) (Nasdaq Stockholm:…

Latest data on lecanemab and exidavnemab to be presented at the 2025 AD/PD™ congress

Stockholm, March 27, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company and partner Eisai…

BioArctic’s partner Eisai presents sales simulation for Leqembi® at its annual press conference

Stockholm, Sweden, March 25, 2025 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published a presentation including…

BioArctic receives Orphan Drug Designation for exidavnemab the US

Stockholm, March 17, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of…

Number of shares and votes in BioArctic AB (publ) as of February 28, 2025

Stockholm, February 28,2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during February issued 139,450…

Leqembi® sales reaches €200 million – first sales milestone achieved

Stockholm, Sweden, February 18, 2025 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has notified BioArctic that the…

FDA approves IV maintenance dosing of Leqembi® (lecanemab-irmb) for the treatment of early Alzheimer’s Disease in the US

Stockholm, January 27, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug…

FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

Stockholm, January 14, 2025 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the U.S. Food and Drug…

BioArctic im Pivotal-Point-Check: Mega-Deal mit Bristol Myers – Bis zu 1,25 Mrd. USD für Alzheimer-Programme!

Die Partnerschaft mit Bristol Myers konzentriert sich auf zwei der Alzheimer-Programme (BAN1503 und BAN2803) der nächsten Generation von BioArctic.…

BioArctic Aktie: Alzheimer-Deal mit Bristol-Myers Squibb

Kulmbach (www.aktiencheck.de) - BioArctic-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die B-Aktie von…

BioArctic surges over 27% on deal with BMS By Investing.com

BioArctic surges over 27% on deal with BMS…

Number of shares and votes in BioArctic AB (publ) as of November 29, 2024

Stockholm, November 29, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during November issued…

Leqembi[®] launched in South Korea

Stockholm, Sweden, November 28, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that Leqembi[®]…

Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 – March 2025). Sales now expected to reach JPY 42.5 billion

Stockholm, Sweden, November 8, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today updated their revenue outlook…

BrainTransporter™ dramatically improves antibody delivery to the brain

Stockholm, Sweden, November 6, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has presented the design of its proprietary…

Invitation to presentation of BioArctic’s third quarter report for July - September 2024 on November 14 at 9.30 a.m. CET

Stockholm, Sweden, November 6, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s third quarter report…

Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

Stockholm, Sweden November 1, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Eisai has…

Lecanemab data presented at CTAD on early initiation and long-term treatment suggest increased patient benefit with maintained safety profile

Stockholm, Sweden October 31, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai has presented the latest findings…

Leqembi® revenue totaled JPY 10 billion in the third quarter 2024

Stockholm, Sweden, October 30, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global…

Professor Lars Lannfelt, awarded the CTAD Lifetime Achievement Award in recognition for his pioneering work in Alzheimers Disease

Stockholm, Sweden, October 30, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that BioArctics co-founder, Professor Lars…

BioArctic AB: The David Against Goliath Of Solving Alzheimers Disease

…

BioArctic presents Nomination Committee

Stockholm, Sweden, October 11, 2024 – Pursuant to the instruction regarding the appointment of the Nomination Committee BioArctic AB’s (publ)…

Number of shares and votes in BioArctic AB (publ) as of September 30, 2024

Stockholm, September 30, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during September issued…

Regarding rumors of an imminent approval of lecanemab in Great Britain

Stockholm, Sweden August 22, 2024 – British media are reporting on the imminent approval of lecanemab in Great Britain. BioArctic…

Invitation to presentation of BioArctic’s second quarter report for April - June 2024 on August 29 at 9.30 a.m. CET

Stockholm, Sweden, August 15, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will publish the company’s second quarter report…

Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates

Stockholm, Sweden, August 14, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that the Ministry…

Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024

Stockholm, Sweden, August 1, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global…

Long-term lecanemab data show increased patient benefit with maintained safety profile

Stockholm, Sweden July 30, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented the latest findings…

Eisai will seek re-examination of CHMP opinion för lecanemab

Stockholm, Sweden July 26, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they will…

CHMP has adopted a negative opinion on lecanemab for the EU

Stockholm, Sweden July 26, 2024 – The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency…

Long-term treatment data for lecanemab to be presented at AAIC 2024

Stockholm, July 23, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that its partner Eisai will present the…

Leqembi approved for the treatment of Alzheimer’s disease in Israel

Stockholm, Sweden, July 12, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqembi® (generic…

Number of shares and votes in BioArctic AB (publ) as of June 28, 2024

Stockholm, June 28, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company during June issued…

FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s Disease

Stockholm, Sweden, June 10, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that that the…

Leqembi[®] approved for the treatment of Alzheimer’s disease in South Korea

Stockholm, Sweden, May 24, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the Ministry of Food…

Bulletin from the Annual General Meeting in BioArctic AB (publ)

Stockholm, 22 May 2024. Today, BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) held its Annual General Meeting in Stockholm today,…

Interim Report for the period January – March 2024

First BrainTransporter technology agreement signed Events during the first quarter 2024 · Leqembi® was approved for the treatment of Alzheimers…

Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025)

Stockholm, Sweden, May 15, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today said that they expect…

Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing

Stockholm, Sweden, May 15, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have…

Leqembi® revenue totaled JPY 2.83 billion in the first quarter 2024

Stockholm, Sweden, April 24, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global…